Patents Assigned to UCL BUSINESS LTD
  • Patent number: 12221482
    Abstract: The invention relates to protein-based T-cell receptor knockdown, and its use in T-cell therapies.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: February 11, 2025
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pule, Paul Maciocia, Ben Grimshaw
  • Patent number: 12209262
    Abstract: The present invention relates to polynucleotides comprising a Factor IX nucleotide sequence, wherein the Factor IX nucleotide sequence comprises a coding sequence that encodes a Factor IX protein or fragment thereof and wherein a portion of the coding sequence is not wild type. The present invention further relates to viral particles comprising a recombinant genome comprising the polynucleotide of the invention, compositions comprising the polynucleotides or viral particles, and methods and uses of the polynucleotides, viral particles or compositions.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: January 28, 2025
    Assignee: UCL Business LTD
    Inventors: Amit Nathwani, Jenny Mcintosh
  • Patent number: 12209114
    Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising a CD21-binding domain, a transmembrane domain and an intracellular domain.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: January 28, 2025
    Assignee: UCL BUSINESS LTD
    Inventor: Martin Pulé
  • Publication number: 20250017950
    Abstract: There is described a compound for use in the treatment of a mitochondrial DNA disorder, wherein the compound is a glycolysis inhibitor, an inhibitor of glutamine consumption or is L-asparaginase or pegaspargase. The glycolysis inhibitor may be a glucose analogue such as 2-deoxy-D-glucose (2DG) or 5-thioglucose (5TG). Also described is a method of treating a mitochondrial DNA disorder comprising administering a therapeutically effective amount of the compound above to a patient suffering from a mitochondrial DNA disorder. In addition, there is described a method of reducing the mtDNA heteroplasmy in the cells of a patient comprising administering a therapeutically effective amount of the compound above to the patient.
    Type: Application
    Filed: November 16, 2022
    Publication date: January 16, 2025
    Applicants: UCL BUSINESS LTD, UNITED KINGDOM RESEARCH AND INNOVATION
    Inventors: Antonella Spinazzola, Ian Holt, Boris Pantic, Daniel Ives
  • Publication number: 20250011844
    Abstract: The invention relates to a method for determining the level and type of mutation events associated with the use of a targeted genetic modification, such as in the use of designer nucleases, to modify a target site of nucleic acid in a cell or virus population. The method comprises carrying out a mutation event determination on a targeted nucleic acid in a population of modified nucleic acids that have been treated with the targeted genetic modification, and a reference control analysis on a non-targeted nucleic acid. The invention further relates to the use of the method for screening of potential targeted genetic modification agents for therapeutic use and to estimate the genomic integrity and stability of a nucleic acid such as a viral vector or genomic DNA.
    Type: Application
    Filed: November 3, 2022
    Publication date: January 9, 2025
    Applicant: UCL Business Ltd
    Inventors: Giandomenico TURCHIANO, Alessia CAVAZZA, Adrian THRASHER, Nathan WHITE
  • Patent number: 12171794
    Abstract: There is described a vector for treating a ciliopathy such as Bardet-Biedl syndrome, wherein the vector comprises a promoter operably linked to a ciliopathy gene, wherein the vector can provide transduction of the ciliopathy gene into multiple organs, wherein the promoter is a ubiquitous promoter which can provide expression of the ciliopathy gene in the transduced organs, and wherein the ciliopathy gene encodes a functional protein corresponding to the protein that is mutated in the ciliopathy. Also described is the use of the above vector in a method of treating a ciliopathy, the method comprising administering a therapeutically effective amount of the vector to a patient suffering from a ciliopathy.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: December 24, 2024
    Assignee: UCL BUSINESS LTD
    Inventors: Philip Beales, Victor Hernandez
  • Patent number: 12165260
    Abstract: Systems and methods are described for rendering garments. The system includes a first machine learning model trained to generate coarse garment templates of a garment and a second machine learning model trained to render garment images. The first machine learning model generates a coarse garment template based on position data. The system produces a neural texture for the garment, the neural texture comprising a multi-dimensional feature map characterizing detail of the garment. The system provides the coarse garment template and the neural texture to the second machine learning model trained to render garment images. The second machine learning model generates a rendered garment image of the garment based on the coarse garment template of the garment and the neural texture.
    Type: Grant
    Filed: April 7, 2022
    Date of Patent: December 10, 2024
    Assignees: Adobe Inc., UCL Business Ltd.
    Inventors: Duygu Ceylan Aksit, Yangtuanfeng Wang, Niloy J. Mitra, Meng Zhang
  • Publication number: 20240404235
    Abstract: A computer-implemented method of enhancing object detection in a digital image of known underlying structure using pre-processed images with underlying structure and with any objects detected and bounding boxes inserted over the objects, the method comprising: extracting or generating images with the underlying structure but without objects detected as negative images; extracting images with the underlying structure and with an object detected as positive images; inputting pairs of negative and positive images through a feature extraction section in a neural network to extract feature vectors of the images; contrasting feature vectors of each pair of positive and negative images and thereby provide a contrast vector and gating the result to form an attention vector; processing the attention vector and the feature vector of the positive image to produce an output.
    Type: Application
    Filed: September 22, 2022
    Publication date: December 5, 2024
    Applicant: UCL BUSINESS LTD.
    Inventors: Watjana LILAONITKUL, Adam DUBIS, James WILLOUGHBY
  • Publication number: 20240401036
    Abstract: Antisense oligonucleotides (ASOs) are provided which are capable of modulating splicing by preventing inclusion of an UNC13A cryptic exon into an UNC13A mature mRNA. Such ASOs may be used as a medicament, for example, to treat neurodegenerative disorders, particularly those associated with TDP-43 pathology.
    Type: Application
    Filed: December 9, 2021
    Publication date: December 5, 2024
    Applicants: UCL BUSINESS LTD, THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Pietro Fratta, Anna Leigh Brown, Oscar Wilkins, Matthew Keuss, Michael Ward, Sarah Hill
  • Publication number: 20240400513
    Abstract: The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as modulators of alpha 1 antitrypsin and treating diseases associated with alpha 1 antitrypsin, particularly liver diseases.
    Type: Application
    Filed: January 26, 2024
    Publication date: December 5, 2024
    Applicant: UCL BUSINESS LTD
    Inventors: Kate SMITH, Alexis DENIS, Nerina DODIC, John LIDDLE, David LOMAS
  • Publication number: 20240395023
    Abstract: A computer-implemented method of active learning for computer vision in digital images, comprising: inputting labelled image training examples into an artificial neural network in a training phase; training a computer vision model using the labelled training examples; carrying out a prediction task on each image of an unlabelled training set of unlabelled, unseen images using the model; calculating an uncertainty metric for the predictions in each image of the unlabelled training set; calculating a similarity metric for the unlabelled training set representing similarities between the images in the training set; selecting images from the unlabelled training set, in dependence upon both the similarity metric and the uncertainty metric of each image, to design a training set for labelling which tends to both lower the similarity between the selected images and increase the uncertainty of the selected images.
    Type: Application
    Filed: September 22, 2022
    Publication date: November 28, 2024
    Applicant: UCL BUSINESS LTD.
    Inventors: Watjana LILAONITKUL, Adam DUBIS, Mustafa ARIKAN
  • Publication number: 20240374757
    Abstract: Provided herein is a composition comprising (i) a nucleic acid sequence encoding a CasRx/Cas13d polypeptide; and (ii) a guide RNA that binds specifically to a target sequence in C9orf72 RNA. Also provided are associated pharmaceutical compositions, guide RNAs, complexes, vectors and cells, and uses of the compositions to neurodegenerative disorders.
    Type: Application
    Filed: April 19, 2022
    Publication date: November 14, 2024
    Applicant: UCL Business Ltd
    Inventors: Liam KEMPTHORNE, Adrian ISAACS
  • Publication number: 20240376501
    Abstract: The inventions related to a method of producing a biomineralized material comprising calcium carbonate-bonded aggregate, the method comprising: culturing a photosynthetic microorganism in a hydrogel matrix, wherein the microorganism releases extracellular carbonic anhydrase into the hydrogel matrix, and wherein the hydrogel matrix comprises: i) a hydrogel; ii) an aggregate material; iii) growth media; and iv) calcium chloride (CaCl2), wherein the extracellular carbonic anhydrase converts the calcium chloride to calcium carbonate precipitate thereby bonding the aggregate material to form the biomineralized material; and associated materials, compositions and uses.
    Type: Application
    Filed: September 16, 2022
    Publication date: November 14, 2024
    Applicant: UCL Business Ltd
    Inventors: Prantar Mahanta TAMULI, Anete Krista SALMANE, Brenda PARKER, Marcos CRUZ, Nina JOTANOVIC
  • Patent number: 12138318
    Abstract: There is described an AAV capsid protein having an amino acid sequence which has at least 98% identity to the sequence of SEQ ID NO: 3 or at least 94% identity to the sequence of SEQ ID NO: 4. Also described is a pharmaceutical composition, an AAV capsid and a viral particle comprising the capsid protein, a recombinant AAV vector comprising a nucleotide sequence which encodes for the capsid protein, and a host cell and a transgenic animal comprising the capsid protein or the vector. In addition, there is described a method of transferring a nucleic acid of interest into a mammal comprising introducing a recombinant AAV vector into the mammal, wherein the recombinant AAV vector comprises a gene of interest which is encapsidated into a capsid comprising the capsid protein.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: November 12, 2024
    Assignee: UCL BUSINESS LTD
    Inventors: Amit Nathwani, Allison Dane
  • Publication number: 20240350444
    Abstract: Decanoic acid for use in treating epilepsy wherein the decanoic acid is used in combination with perampanel, or a pharmaceutically acceptable salt thereof, or wherein the decanoic acid is used in combination with an AMPA receptor inhibitor that binds to the same AMPA receptor site as perampanel.
    Type: Application
    Filed: June 27, 2024
    Publication date: October 24, 2024
    Applicant: UCL BUSINESS LTD
    Inventors: Robin Simon Brooke Williams, Matthew Walker
  • Publication number: 20240352488
    Abstract: A guide RNA comprising (17) to (24) nucleotides which are complementary to exon 1 of the human SH2D1A or the complement thereof. Ribonuclear proteins (RNP) complexes comprising the guide RNA and a Cas nuclease, and gene editing kits comprising the ribonuclear protein (RNP) complexes are also disclosed, including the use of these components in therapy, particularly for SAP-mediated diseases.
    Type: Application
    Filed: October 17, 2022
    Publication date: October 24, 2024
    Applicant: UCL BUSINESS LTD
    Inventors: Claire BOOTH, Benjamin C. HOUGHTON
  • Patent number: 12121989
    Abstract: A method for making a housing that defines a cavity for a pressure sensor, the method comprising: providing a bulk of material that will form the housing; focusing a radiation beam on internal portions of the bulk of material so as to modify the internal portions, thereby defining the housing's shape, wherein upstream of the focus of the radiation beam other portions of the bulk material remain unmodified; and discarding either the modified portions or the unmodified portions of the bulk material so as to form the cavity.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: October 22, 2024
    Assignee: UCL BUSINESS LTD
    Inventors: Adrien Desjardins, Malcolm Finlay, Charles Alexander Mosse, Ioannis Papakonstantinou, Radhika Poduval
  • Publication number: 20240344072
    Abstract: The disclosure relates to a method of treating a disorder of the tyrosine degradation pathway in a subject, and a composition for use in said method. The disclosure also relates to a nucleic acid silencing molecule that reduces the expression of an enzyme involved in the tyrosine degradation pathway.
    Type: Application
    Filed: July 4, 2022
    Publication date: October 17, 2024
    Applicant: UCL BUSINESS LTD
    Inventors: Haiyan Zhou, Paul Gissen, Bruno Doreste
  • Publication number: 20240324931
    Abstract: Disclosed is an electrocardiographic imaging (ECGi) system including an electrode vest (100) that comprises a flexible base layer (110) configured to cover at least a patient's chest area; and a plurality of dry contact electrodes (120) attached to the flexible base layer (110) and distributed over at least a chest area of the flexible base layer (110) to acquire electrophysiological signals from the patient's skin surface. Each electrode (120) comprises a sensing portion having an exposed sensing surface on an interior skin facing side of the electrode to contact the user's skin surface when the vest is worn, and an exposed connector portion on an exterior side of the electrode for removably connecting with an electrical lead of an ECGi measurement apparatus.
    Type: Application
    Filed: March 31, 2023
    Publication date: October 3, 2024
    Applicant: UCL Business Ltd
    Inventors: Gabriella Captur, George Joy, Matthew Webber, Pier Lambiase, Michele Orini
  • Patent number: 12102431
    Abstract: A method of determining the perceptual load of a human brain. The perceptual load is induced by a predetermined task carried out by the human. The method includes the steps of: measuring with a functional near-infrared spectroscopy (fNIRS) sensor device a metabolic activity of the human brain while the task is carried out and determining the perceptual load as a function of a measured change in metabolic activity. The invention further relates to a method of determining the level of stimulus perception corresponding systems.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: October 1, 2024
    Assignees: TOYOTA JIDOSHA KABUSHIKI KAISHA, UCL BUSINESS LTD
    Inventors: Jonas Ambeck-Madsen, Nilli Lavie, Merit Bruckmaier, Ilias Tachtsidis